Neuroinflammatory Mechanisms in Depression: From Biomarkers to Anti-Inflammatory Therapy

Area of Science:

• Neuroscience
• Psychiatry
• Immunology

Background:

• Major depressive disorder (MDD) is a prevalent, complex psychiatric condition.
• Neuroinflammation is increasingly recognized as a significant factor in MDD pathophysiology.
• Distinct inflammatory profiles may underlie heterogeneity in MDD clinical presentation and treatment response.

Purpose of the Study:

• To review the contribution of neuroinflammatory processes to depression.
• To explore biomarkers for identifying clinically relevant inflammatory phenotypes in MDD.
• To discuss how these insights can inform targeted anti-inflammatory treatment strategies for depression.

Main Methods:

• Narrative review of current scientific literature.
• Integration of evidence on neuroinflammatory mechanisms in depression.
• Discussion of candidate biomarkers and their clinical utility.
• Analysis of anti-inflammatory treatment strategies in MDD.

Main Results:

• Neuroinflammation involves microglial activation, HPA axis dysregulation, kynurenine pathway alterations, and cytokine effects on neurogenesis and plasticity.
• These pathways interact with stress, neurotransmitters, and neuronal function, influenced by factors like sex and age.
• Candidate biomarkers include CRP, IL-1β, IL-6, TNF-α, BDNF, and TGF-β for patient stratification and treatment prediction.
• Anti-inflammatory agents have shown modest effects in unselected MDD populations.

Conclusions:

• Neuroinflammatory pathways significantly contribute to depressive symptoms by disrupting neural function and plasticity.
• Biomarkers are crucial for stratifying MDD patients and predicting treatment response to anti-inflammatory therapies.
• Integrating mechanistic and biomarker data can lead to more precise, individualized treatment strategies for major depressive disorder.